Sciwind Biosciences Partners with Pfizer China to Commercialize its Biased GLP-1 in China
HANGZHOU, China, Feb. 24, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences") today announced a strategic commercialization collaboration with Pfizer China for Ecnoglutide injection (Ecnoglutide), a new–generation cAMP–biased GLP–1 receptor agonist. Under the agreement, Pfizer will obtain exclusive commercialization rights for the product in Mainland China, marking an important first step to advance Pfizer's global strategy...
NYSE Content Update: Stock Market to Open Like Normal Amid Historic NYC Blizzard
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Feb. 23, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. John...
ZEISS launches Collaborative Care application to strengthen continuity of care; new solution offers on-premises and cloud-based options
Built on the ZEISS Health Data Platform, ZEISS Collaborative Care offers eye care professionals a flexible way to collaborate – whether as a standalone cloud application or as an integrated extension of ZEISS FORUM – enabling secure data sharing, structured referrals, and real-time clinical coordination to strengthen continuity of care across the...
“Would You Clone Yourself for a Cure?” Clonell Unveils White Paper on Fundamental Cures for 34 Incurable Diseases Using ‘Human Cloning’ Technology
Harnessing the vitality of a clone while neutralizing ethical controversies through a breakthrough 'Therapeutic Cloning' protocol—ushering in a new era of regenerative medicine to conquer cancer, Alzheimer's, and aging. YONGIN, South Korea, Feb. 23, 2026 /PRNewswire/ -- Human cloning has long been a subject of dystopian science fiction and a stringent ethical...
iRegene Hits Dual Global Firsts: U.S. Patient Dosed in Phase IIa for NouvNeu001 in Parkinson’s and First Enrollment in China’s Randomized MSA Trial for NouvNeu004
CHENGDU, China, Feb. 23, 2026 /PRNewswire/ -- The global race to treat neurodegenerative diseases has reached a new tempo as iRegene Therapeutics pushes its cell therapy pipeline into key clinical stages in the U.S. and China. Concurrently, the company's "AI + Chemical Induction" platform saw its first U.S. patient dosed for Parkinson's disease at Weill Cornell Medical Center and...
Formosa Pharmaceuticals Announces Licensing Agreement with Arrotex, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
TAIPEI, Feb. 23, 2026 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Arrotex Pharmaceuticals Pty Ltd. ("Arrotex"), for exclusive rights to the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), an innovative topical eyedrop for the treatment of inflammation and pain following...
Herbalife Announces Cristiano Ronaldo Invests $7.5 Million in Pro2col™ Technology, Acquires 10% Equity Stake
Long-time partner invests in shared vision for personalized health and wellness HONG KONG, Feb. 23, 2026 /PRNewswire/ -- Herbalife Ltd. (NYSE: HLF), a premier health and wellness company, community and platform, announced global sports icon Cristiano Ronaldo acquired a 10% equity interest in HBL Pro2col Software, LLC, an indirect wholly-owned subsidiary of Herbalife that...
Vitafoods Asia 2026 Expands by 30%: A Bigger, More Dynamic Trade Event with Exciting New Features & Increased International Participation
BANGKOK, Feb. 23, 2026 /PRNewswire/ -- With a remarkable 30% growth in size and participation, Vitafoods Asia 2026 organised by Informa Markets, is set to redefine the nutraceutical industry in Asia, offering unparalleled opportunities for innovation and collaboration. The event will feature an exhibit space of 30,000 square meters with over 800...
CStone Announces MHRA Approval in UK for Sugemalimab in Stage III NSCLC
Following approval by the European Commission (EC), sugemalimab has received a new indication approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for stage III non-small cell lung cancer (NSCLC). This marks the second indication approved for the product in the UK. This approval is based on the GEMSTONE-301 study, a multicenter, randomized, double-blind Phase III trial....
HeyGears Announces One-Piece Denture Solution – Redefining Digital Dentures with Dual-Material 3D Printing
HeyGears' One-Piece Denture Solution enables dual-material denture DLP 3D printing, seamlessly fusing denture base and teeth materials in a single printing process to deliver more natural aesthetics and a comfortable fit. CHICAGO, Feb. 20, 2026 /PRNewswire/ -- HeyGears announces breakthrough One-Piece Denture Solution at LMT LAB DAY Chicago.   HeyGears' One-Piece Denture Solution breaks through the technological...
